Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by IRISSIRIOUSon Jan 19, 2017 1:44pm
98 Views
Post# 25729287

RE:RE:QUESTION for ANYONE.

RE:RE:QUESTION for ANYONE.ALWAYS — Thanks for that thorough post.  However, I don't think you've made tha case that one form of detection is greater that the other, when ultimately, diabetes is a condition whereby a lack of blood sugar/insulin mangement could have very serious, negative outcomes — not the least of which, could be blindness.  This is to say then, that this test does not help prevent the incidence of blindness (specificallly), but rather provides a tool for detection of diabetes, as a whole. That said, if instead, it all really comes down to a question of accessibility, expedience, convenience, market penetration, and ultimately, cost feasibility, then that would appear to be a different story altogether — and it will be those variables that I would factor into whether or not to stay long on ADK.  Fair?
Bullboard Posts